entertainment -WSS

entertainment

author：comprehensive 2025-09-06 02:06:01 - browse：94963

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

WSS

Biden launches a new push to limit health care costs

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

NIH fellows want a pay raise. Will that mean less money for grants?

How many hemophilia patients actually want gene therapy?

Palantir health business leans on meeting customers’ needs

N.Y. state detects polio case, first in the U.S. since 2013

explore

entertainment

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

HCA discloses massive data breach affecting 11 million patients

Peter Hotez and the public health issue of online harassment

Boston's new lab space is opening empty

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

RaDonda Vaught links Vanderbilt hospital issues to patient death

As demand for Covid shots wanes, Moderna seeks its next success

Why ADHD is under

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Living with Fabry disease, a condition that causes chronic pain

focus

Why ADHD is under

What to know about OceanGate, the company behind the missing Titanic submersible

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

As AI in medicine takes off, can 'human in the loop' prevent harm?

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Readout Newsletter: CAR

hotspot

focus

hotspot

explore